Related Experiment Video
Updated: Jun 24, 2025
08:24
Isolation and Identification of Extravascular Immune Cells of the Heart
Published on: August 23, 2018
13.0K
Immune cell phenotypes and mortality in the Framingham Heart Study
Ahmed A Y Ragab1, Margaret F Doyle2, Jiachen Chen3
1Department of Biostatistics, School of Public Health, Boston University, Boston, MA, USA. aragab@bu.edu.
Immunity & Ageing : I & A
|June 12, 2024
Summary
Aging immune cell phenotypes, like CD4/CD8 ratios, are linked to mortality risk. Elevated IL-6 levels consistently correlate with increased mortality, highlighting immune system aging
Area of Science:
- Immunology
- Gerontology
- Epidemiology
Background:
- Global life expectancy is increasing, with a growing elderly population.
- Immune system aging is marked by Aging-Related Immune Cell Phenotypes (ARIPs).
- The relationship between immune cell phenotypes and mortality remains underexplored.
Purpose of the Study:
- To investigate the association between 16 immune cell phenotypes and survival.
- To examine the role of Interleukin-6 (IL-6) in mortality risk.
- To analyze data from dementia-free Framingham Heart Study (FHS) offspring cohort.
Main Methods:
- Prospective study of 996 FHS participants (mean age 62).
- Flow cytometry used to assess 16 immune cell phenotypes.
- IL-6 levels measured, and survival outcomes tracked over 19 years.
Main Results:
- Higher CD4/CD8 and Tc17/CD8+Treg ratios associated with lower mortality.
- Higher CD8+CD25+FoxP3+ (CD8+Treg) levels linked to increased mortality.
- Elevated IL-6 correlated with higher all-cause, cardiovascular, and non-cardiovascular mortality.
- Associations between immune cell phenotypes and mortality disappeared after adjusting for confounders, but IL-6 remained significant.
Conclusions:
- Specific immune cell phenotypes (CD4/CD8, Tc17/CD8+Treg, CD8+Treg) show differential associations with mortality.
- Elevated IL-6 levels consistently predict increased mortality risk.
- Findings suggest implications for future research and clinical considerations in immune system aging and mortality.
